Form 4: Passage Bio CFO Kathleen Borthwick Acquires 227,000 Stock Options

Kathleen Borthwick, CFO of Passage Bio, Inc., reports the acquisition of 227,000 employee stock options on March 15, 2024.

Summary

• Kathleen Borthwick, the CFO of Passage Bio, Inc. (PASG), filed a Form 4 with the SEC on March 19, 2024.
• The filing reports a transaction that occurred on March 15, 2024, where Borthwick acquired 227,000 employee stock options.
• The exercise price of each option is $1.50.
• The options vest monthly, starting April 15, 2024, over a period of 48 months, contingent upon Borthwick's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the CFO to the company, as the options vest over a 48-month period.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing is typical for executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by the CFO could potentially align her interests with those of the shareholders.

Key Dates